Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 2/20 | 0.47 |
| ▸ | PLAU | P00749 | 1/20 | 0.44 |
| ▸ | NCF1 | P14598 | 1/20 | 0.44 |
| ▸ | DHFR | P00374 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1784500 | 0.93 | DHFR (0.44) | METAP2PLAUNCF1DHFRALDH1A1 | |
| SCHEMBL12827741 | 0.87 | METAP2 (0.46) | METAP2PLAUNCF1ALDH1A1CYP1A2 | |
| SCHEMBL1507976 | 0.82 | DHFR (0.49) | DHFRALDH1A1KDM4ETSHRTLR8 | |
| SCHEMBL1507775 | 0.76 | PDE10A (0.46) | DHFRALDH1A1HPGDKMT2ALMNA | |
| SCHEMBL15886634 | 0.76 | NCF1 (0.56) | NCF1DHFRCYP1A2HIF1ATLR8 | |
| SCHEMBL3230745 | 0.75 | METAP2 (0.58) | METAP2PLAUNCF1ALDH1A1CYP1A2 | |
| SCHEMBL8344571 | 0.75 | METAP2 (0.58) | METAP2PLAUNCF1ALDH1A1CYP1A2 | |
| SCHEMBL5671692 | 0.74 | METAP2 (0.45) | METAP2PLAUNCF1ALDH1A1CYP1A2 | |
| SCHEMBL1160443 | 0.73 | METAP2 (0.51) | METAP2PLAUNCF1ALDH1A1CYP1A2 | |
| SCHEMBL6051279 | 0.72 | KCNH2 (0.56) | METAP2PLAUNCF1ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009140215-A2 | METHOD FOR TREATING DRUG-RESISTANT BACTERIAL AND OTHER INFECTIONS WITH CLIOQUINOL, PHANQUINONE, AND RELATED COMPOUNDS | GERAGHTY, ERIN (US) | 2009-11-19 | — | — | WO | claimed |
| US-20240148918-A1 | Loading of Alginate Microspheres | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2024-05-09 | — | — | US | disclosed |
| EP-4301341-A1 | LOADING OF ALGINATE MICROSPHERES | Board of Regents, The University of Texas System (US) | 2024-01-10 | — | — | EP | disclosed |
| US-11701374-B1 | 8-hydroxy quinoline derivatives for enhancing telomerase reverse transcriptase (TERT) expression | SIERRA SCIENCES, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11701374-B1 | 8-hydroxy quinoline derivatives for enhancing telomerase reverse transcriptase (TERT) expression | SIERRA SCIENCES, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| WO-2022187683-A1 | LOADING OF ALGINATE MICROSPHERES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-09-09 | — | — | WO | disclosed |
| WO-2021116712-A1 | FUNCTIONALISED MICROBUBBLE MEDIATED CELL TAGGING | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2021-06-17 | — | — | WO | disclosed |
| EP-2453927-B1 | LOADING TECHNIQUE FOR PREPARING RADIONUCLIDE AND IONOPHORE CONTAINING LIPOSOMES IN WHICH THE IONOPHORE IS 2-HYDROXYQUIONOLINE (CARBOSTYRIL) OR STRUCTURALLY RELATED 2-HYDROXYQUINOLINES | UNIV DENMARK TECH DTU (DK) | 2019-05-15 | — | — | EP | disclosed |
| EP-2651447-B1 | ENTRAPMENT OF RADIONUCLIDES IN NANOPARTICLE COMPOSITIONS | UNIV DENMARK TECH DTU (DK) | 2018-08-29 | — | — | EP | disclosed |
| US-20160158392-A1 | Entrapment of Radionuclides in Nanoparticle Compositions | RIGSHOSPITALET (DK) | 2016-06-09 | — | — | US | disclosed |
| US-7619091-B2 | Treating nervous system disorders such as mild cognitive impairment, Alzheimer's disease or dementia associated with Down syndrome; e.g. use of 5,7-dichloro-8-hydroxy-2-(2-pyridyl)-quinoline (PBT 1052) | PRANA BIOTECHNOLOGY LIMITED (AU) | 2009-11-17 | — | — | US | disclosed |
| US-20090227626-A1 | NOVEL POLYQUINOLINE DERIVATIVES AND THERAPEUTIC USE THEREOF | PALUMED S.A. (FR) | 2009-09-10 | — | — | US | disclosed |
| US-20080161353-A1 | 8-Hydroxy quinoline derivatives | PRANA BIOTECHNOLOGY LIMITED (AU) | 2008-07-03 | — | — | US | disclosed |
| US-20080161353-A1 | 8-Hydroxy quinoline derivatives | PRANA BIOTECHNOLOGY LIMITED (AU) | 2008-07-03 | — | — | US | disclosed |
| EP-1919894-A2 | NOVEL POLYQUINOLINE DERIVATIVES AND THE THERAPEUTIC USE THEREOF | Palumed SA (FR) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007015017-A2 | NOVEL POLYQUINOLINE DERIVATIVES AND THE THERAPEUTIC USE THEREOF | PALUMED S.A. (FR) | 2007-02-08 | — | — | WO | disclosed |
| US-6294273-B1 | EXHIBITS HOLE-INJECTING, HOLE-TRANSPORTING, ELECTROLUMINESCENT, ELECTRON-TRANSPORTING, AND ELECTRON-INJECTING FUNCTIONS, WHEREIN THE HOLE INJECTION ZONE CONTAINS AN UNCHARGED OR CATIONIC POLYTHIOPHENE | BAYER AKTIENGESELLSCHAFT (DE) | 2001-09-25 | — | — | US | disclosed |
| US-6287713-B1 | CONTAINING POLYTHIOPHENE | BAYER AKTIENGESELLSCHAFT (DE) | 2001-09-11 | — | — | US | disclosed |
| EP-0969531-A2 | Electroluminescent devices comprising boron chelates | Bayer Aktiengesellschaft (DE) | 2000-01-05 | — | — | EP | disclosed |
| EP-0964459-A2 | Electroluminescent devices containing N-alkyl-2,2'-imino-bis-(8-hydroxy-quinoline) metal complexes | Bayer Aktiengesellschaft (DE) | 1999-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161353-A1 | 8-Hydroxy quinoline derivatives | PARK7, COQ8A, NLN | METAP2 1832/4885PLAU 2218/4885NCF1 2693/4885 |
| US-11701374-B1 | 8-hydroxy quinoline derivatives for enhancing telomerase reverse transcriptase (TERT) expression | TERT, TERF2, RNGTT | METAP2 1330/4885PLAU 3003/4885NCF1 2599/4885 |
| US-20090227626-A1 | NOVEL POLYQUINOLINE DERIVATIVES AND THERAPEUTIC USE THEREOF | HTT, UBQLN2, UBQLN1 | METAP2 4011/4885PLAU 3086/4885NCF1 1965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.